An independent study into how the National Institute for Health and Clinical Excellence (NICE) establishes the value of innovation has been published, and was presented by Sir Ian Kennedy at the public NICE Board meeting on July 22.
The report, carried out by Sir Ian Kennedy, provides several recommendations including how NICE can ensure its approach to establishing the value of new health technologies takes innovation into account and how innovation in health technologies should be defined. It report was commissioned in response to the views expressed by Sir David Cooksey in his Review and Refresh of Bioscience 2015. As part of the study interested parties – including the ABPI, NICE, a number of pharmaceutical companies and several patient groups – provided submissions.
This was followed up with a number of workshops exploring key issues with representatives from the NHS, healthcare professionals, healthcare industries, patients and the wider public. NICE’s Citizen’s Council also contributed its views to the study.
NICE chairman, professor Sir Michael Rawlins said: “We are very grateful to Sir Ian for his report on the value of innovation, and for broad confidence he has expressed in NICE and its methods. Since NICE was established we have regularly consulted on our approach to valuing the benefits of new technologies and we welcome the opportunity to focus on innovation. Sir Ian’s report raises a number of issues that NICE will need to consider. NICE’s Board will set out a formal response at its next public Board meeting in September, which will then be the subject of a three-month consultation.”